Eledon is dedicated to “One Transplant For Life” to significantly improve both the longevity of the organ and the overall health and quality of life for transplant recipients so that a donor’s greatest gift will keep on giving.
Our lead compound is tegoprubart, an anti-CD40L antibody with broad therapeutic potential to regulate the drivers that can lead to the immune system attacking and rejecting transplanted organs.
Targeting a more successful transplant experience. For life.
A successful transplant is just the beginning. The current immunosuppressive therapies that keep a new organ working are essential, but over time they can take a toll, causing serious side effects like kidney damage, diabetes, high blood pressure, headaches, and tremors. For decades, this trade-off has gone largely unchallenged.
At Eledon, we believe it doesn’t have to be this way. We’re developing a next generation immunosuppression therapy designed to protect transplanted organs while reducing the lifelong burden of immunosuppression, so a transplant can mean not just more years, but better ones.
At Eledon our mission is One Transplant for Life.
“There has been little innovation in immunomodulatory therapy for organ transplants since the approval of tacrolimus over 30 years ago. Organ transplant recipients deserve better. Targeting the CD40 Ligand pathway may provide significant advantages over current treatment options, including the ability to more effectively control immune response and increase transplant durability.”
